ProPhase Labs, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Share (Tables)

Earnings (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Basic and Diluted Net Loss Per Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

	December 31, 2021		December 31, 2020
	For the years ended
	December 31, 2021		December 31, 2020
Net income (loss) - basic	$	6,273	$	(2,125	)
Interest on unsecured convertible promissory note		1,000		-
Net income (loss) - diluted	$	7,273	$	(2,125	)
Weighted average shares outstanding - basic		15,172		11,595
Diluted shares- Stock Options		2,001		-
Diluted shares- Stock Warrants		220		-
Unsecured convertible promissory note		1,000		-
Weighted average shares outstanding - diluted		18,393		11,595

Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

	December 31, 2021		December 31, 2020
	For the years ended
Anti-dilutive securities	December 31, 2021		December 31, 2020
Common stock purchase warrants		455		450
Stock Options		828		3,795
Unsecured convertible promissory note		-		1,000
Anti-dilutive securities		1,283		5,245